Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Type 3 inflammation–specific keratinocyte glutaminolysis promotes skin inflammation
Yongfei Hu, Hai Yu, Kaiyu Liang, Liyan Yuan, Wenjun Zhang, Zhe Zhuang, Suyun Ji, Xichun Xia
Yongfei Hu, Hai Yu, Kaiyu Liang, Liyan Yuan, Wenjun Zhang, Zhe Zhuang, Suyun Ji, Xichun Xia
View: Text | PDF
Research Article Dermatology Metabolism

Type 3 inflammation–specific keratinocyte glutaminolysis promotes skin inflammation

  • Text
  • PDF
Abstract

Inflammatory cytokines reprogram keratinocyte metabolism, but the metabolic pathways that couple immune signals to pathological epidermal growth remain incompletely defined. Here, we identify glutaminase 1–mediated (GLS1-mediated) glutaminolysis as a metabolic program preferentially induced in keratinocytes under type 3 inflammatory conditions. Integrated transcriptomic, metabolomic, genetic, and functional analyses showed that IL-17A induced GLS1 expression and glutaminolysis in keratinocytes. Keratinocyte-specific Gls1 deletion reduced the intracellular availability of arginine, proline, and methionine, impaired amino acid–dependent mTORC1 activation, disrupted redox homeostasis, and limited keratinocyte proliferation. Amino acid or antioxidant supplementation partially rescued these defects, whereas rapamycin blocked the amino acid–mediated proliferative rescue. Gls1 deletion did not impair steady-state skin development or homeostasis and did not alter MC903-induced type 2 dermatitis, but it delayed wound re-epithelialization and attenuated imiquimod-induced psoriasiform inflammation. Loss of keratinocyte GLS1 also reduced epidermal chemokine expression and the accumulation of neutrophils and IL-17A–producing γδ T cells, revealing a role for glutaminolysis in amplifying epithelial-immune crosstalk. These findings define GLS1-mediated glutaminolysis as a context-specific metabolic checkpoint linking type 3 inflammation to keratinocyte proliferation and cutaneous immune amplification, and support locally or temporally controlled GLS1 inhibition as a potential therapeutic strategy for psoriasis.

Authors

Yongfei Hu, Hai Yu, Kaiyu Liang, Liyan Yuan, Wenjun Zhang, Zhe Zhuang, Suyun Ji, Xichun Xia

×

Figure 1

Glutaminolysis is preferentially activated in keratinocytes under cutaneous type 3 inflammation.

Options: View larger image (or click on image) Download as PowerPoint
Glutaminolysis is preferentially activated in keratinocytes under cutane...
(A) UMAP visualization of keratinocyte subclustering in the human psoriasis scRNA-seq dataset (GSE173706). Split UMAP plots illustrate the distribution of these cell types across psoriasis (Pso) and healthy control (HC) groups. (B) Bar chart illustrating the absolute cell numbers of various epithelial subpopulations in HC and Pso groups from dataset GSE173706. (C) Dot plot illustrating the functional enrichment of genes significantly upregulated in Pso versus HC across 3 distinct basal keratinocyte clusters. (D) UMAP dot plots showing the activity scores of the glutamate and glutamine metabolism gene set in Pso and HC groups. Scoring was quantified at single-cell resolution using the AUCell algorithm. (E) Violin plots depicting the distribution of AUCell-derived activity scores for the glutamate and glutamine metabolism gene set across various keratinocyte subpopulations. Statistical differences between Pso and HC within each cell type were evaluated using the Wilcoxon rank-sum test. *P < 0.05, **P < 0.01. (F) GSEA showing significant upregulation of glutaminolysis in psoriatic basal keratinocytes compared with HC (left panel), and in psoriatic basal versus spinous keratinocytes (right panel). (G) UMAP visualization of keratinocyte subclustering in the mouse psoriasis-like model scRNA-seq dataset (CRA033085), including the subdivision of the Basal cluster into Basal I and Basal II. Split UMAP plots depicting the distribution of keratinocyte subclusters in IMQ-treated and normal control groups, revealing comparable cell numbers for each subcluster across conditions. (H) Bar plot illustrating GO enrichment analysis of upregulated DEGs in Basal keratinocyte between IMQ and normal groups. (I) GSEA showing significant upregulation of glutaminolysis in IMQ-treated basal keratinocytes.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts